miR-21 | AS patients | RECK,PDCD4, and TGF-β | Predicts myocardial collagen expression | [121] |
MI mice | Jagged1 | CFs?myofibroblasts transformation↑, myocardial fibrosis ↑ | [122] |
Cardiac allograft transplantation model | PTEN/AP-1 pathway | Fibrosis gene program ↑, monocytes-fibroblasts transformation ↑ | [123] |
LVNC paitients | — | Plasma miR-21, miR-29a, miR-30d and miR-133a↑ | [124] |
miR-29 | Pathological hypertrophy model | — | Cardiac miR-29a, mir-29c ↓ | [127] |
Cardiac hypertrophy mice | — | Prevented Col1a1, Col1a2 and Col3a1 expression | [128] |
miR-1 | Myocardial hypertrophy model | FBLN2 | Cardiac remodeling ↓ | [129] |
miR-378 | TAC rats | Paracrine mechanisms | Cardiac fibrosis ↓ | [130] |
miR-203 | DCM rats | PI3K/Akt signaling pathway | Prevented cardiac Col I, Col III expression | [131] |
miR-135a | Cardiac hypertrophy model | TGF-β/Smads pathway | Associated with the α-SMA and Co I | [132] |
miR-135a, miR-202-3p, miR-122, miR-195 and miR-328 | Fibrosis model | TGFβ1 signaling pathway | Involved in the progression and development of myocardial fibrosis | [132-136] |
miR-197-5P | HF patients | — | miR-197-5P↑, associated with adverse cardiac events | [138] |
miR-208, miR-499 | AMI paitients | — | Mediates cardioblasts?cardiomyocytes transformation and muscle fiber specification | [139] |
miR-101, miR-150 | MI rats | — | Cardiac miR-101 and miR-150 ↓ | [140-141] |
miR-144 | MI model | — | miR-144 deletion: cardiac collagen content ↑, cardiac function ↓ | [142] |
miR-101a | MI rats | — | Intermittent aerobic exercise: cardiac miR-101a ↑ | [143] |